Credits Available: 4.5 AMA PRA Category 1 Credit™ & 4.5 MOC Points

Description: This collaborative social learning platform establishes a network of providers who can support each other locally, as well as those from different communities, to learn and share best practices that will improve outcomes for patients with advanced and metastatic urothelial carcinoma. Advanced and metastatic urothelial carcinoma (a/mUC) of the bladder comprises a small subset of all urothelial tumors but accounts for the majority of the rapid mortality associated with this disease. Over the last decade, accelerating basic science research has enabled a deeper understanding of the molecular biology of urothelial tumors, leading to the development of novel treatment strategies. Immune checkpoint inhibitors (ICIs) have demonstrated encouraging results in the first-line and second-line treatment of mUC as well as in treatment-naïve cisplatin-ineligible patients with some durable responses and a favorable toxicity profile when compared to further chemotherapy. More recently, a new ICI/antibody-drug conjugate (ADC) combination has been approved. Given these changes, educational gaps exist for clinicians treating patients with advanced or metastatic UC in the areas of (1) determining cisplatin/platinum eligibility, (2) use of immuno-oncologic (IO) agents and IO/ADC combinations, and (3) managing adverse events associated with these treatments. This social learning experience will address these gaps and provide the opportunity to collaborate.

CME/CE Accreditation Information

If you already have a Gather-ed account, please login

Email:
Password:

Register

Step 1 of 3

This program is intended for:
Target Professions: DO, MD, Nurse, Nurse Practitioner, Physician Assistant
Target Specialties: Oncology
Group Leader

Terence Friedlander

UCSF Medical Center

I am a Professor of Medicine at the University of California San Francisco and an academic medical oncologist focused on developing novel treatments for urologic cancers and improving cancer care for all patients.

 

Group Co-Leader

Vadim Koshkin

University of California San Francisco
Assistant Professor

Vadim Koshkin is a genitourinary medical oncologist at the University of California San Francisco where he co-leads the bladder cancer clinical program in medical oncology. He completed his medical school at the University of Chicago Pritzker School of Medicine, internal medicine training at the University of Michigan and oncology fellowship at the Cleveland Clinic. He started as faculty at the University of California San Francisco (UCSF) in 2018, focusing on the care of patients with GU malignancies and on building the bladder cancer program. His research interests have focused on clinical trials, targeted agents and biomarkers in bladder cancer, as well as radioligand therapies and imaging in bladder and prostate cancer. He is co-leading the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study, a large, multi-institutional, retrospective study of patients with advanced urothelial cancer treated with novel targeted agents. At UCSF he serves as the co-chair of the Molecular Imaging & Radionuclide Therapy site committee. Dr. Koshkin is the recipient of the Prostate Cancer Foundation Young Investigator Award, is the author of numerous publications including first author manuscripts in JCO, Clinical Cancer Research, Cancer and JITC, and has presented his research at national and international conferences.